Study pelvic conditions with programmable thermal neuromodulation.
H3Pelvic partners with hospitals, universities, pelvic health clinics, and translational research teams to evaluate controlled thermal dosing across high-burden pelvic and tissue-related conditions.
Thermal range
2–45°C
Cold / contrast protocols
Warming protocols
Ramp-rate control
Home-use workflow
Study-ready logs
13
indications mapped
$44.6B
current markets
$2.15B
3% SAM scenario
Program components
Built for investigators, not just procurement.
The H3Pelvic Academic Program packages device access with the practical materials institutions need to start well-designed feasibility, pilot, and investigator-initiated studies.
Research-ready device access
H3Pelvic systems configured for investigator-led thermal neuromodulation studies, including protocol presets and controlled temperature ranges.
Protocol design support
Study scoping, endpoint selection, dosing schedules, sham/control planning, feasibility timelines, and IRB-ready technical summaries.
Academic pricing
Institutional pricing for pilot studies, multi-site trials, resident projects, and translational research programs.
Data collection templates
Suggested patient-reported outcome instruments, adverse event tracking, adherence logs, and visit schedule templates.
Collaboration & publications
Optional collaboration on protocol development, data interpretation, abstracts, manuscripts, and grant submissions.
Compliance-minded materials
Positioned for research and investigational use. No disease claims are implied; clinical use depends on regulatory and IRB determinations.
Research directions
Nine study pathways for pelvic health institutions.
Each pathway can be adapted for feasibility work, randomized controlled trials, registry studies, or grant-backed collaborations.
Inflammation & Pain Modulation
Thermal dosing, symptom tracking, inflammatory markers, analgesic response, rescue-medication reduction.
Pelvic Floor & Neuromuscular Recovery
Spasm relief, muscle tone, mobility, pelvic-floor therapy augmentation, responder profiling.
Bladder & Urogenital Syndromes
Interstitial cystitis, chronic prostatitis, dysuria, urgency, quality-of-life endpoints.
Women’s Pelvic Health
Dysmenorrhea, vulvodynia, endometriosis-associated pain, cycle-aware protocols.
Wound & Tissue Recovery
Hemorrhoids, fissures, pressure sores, perfusion, comfort, healing-adjacent endpoints.
Dose-Response & Thermal Physiology
2–45°C protocol libraries, ramp rates, exposure duration, thermal tolerance and safety.
Home-Use Adherence
Remote-use workflow, patient-reported outcomes, wear time, safety check-ins, telehealth workflows.
Closed-Loop Personalization
Temperature feedback, patient input, adaptive program selection, future biosignal integrations.
Health Economics & Access
Site-of-care shift, reduced visit burden, productivity, institutional procurement pathways.
Institutional opportunity map
Prioritize the conditions with the strongest research timing.
A research-facing view of market size, growth, serviceable obtainable market assumptions, and suggested timing for trial-data generation.
| Indication | Current market | CAGR | 10-year future market | SAM @ 3% TAM | Trial-data timing |
|---|---|---|---|---|---|
| Chronic Prostatitis | $5.0B | 9.0% | $9.96B | $298.9M | 2027 |
| Dysmenorrhea | $5.84B | 8.4% | $11.13B | $334.0M | 2027 |
| Hemorrhoids | $5.7B | 7.5% | $9.46B | $283.7M | 2027 |
| Interstitial Cystitis | $2.0B | 5.6% | $2.77B | $83.2M | 2026 |
| Pressure Sores | $5.5B | 5.3% | $7.50B | $224.9M | 2029 |
| Erectile Dysfunction | $2.92B | 8.3% | $5.53B | $165.8M | 2030 |
| Vulvodynia | $4.1B | 6.8% | $6.50B | $194.9M | 2027 |
| Endometriosis | $1.7B | 4.5% | $2.41B | $72.2M | 2028 |
| Pelvic Floor Spasms | $1.5B | 4.4% | $1.94B | $58.3M | 2028 |
| Fistula / Fissures | $1.9B | 6.2% | $3.07B | $92.2M | 2028 |
| Candida Infections | $4.3B | 4.7% | $5.66B | $169.9M | 2028 |
| PID | $3.5B | 4.4% | $4.73B | $141.9M | 2030 |
| Testicular Cancer | $686M | 8.4% | $873.8M | $26.2M | 2029 |
Market assumptions should be validated before external use. This section is structured for internal prioritization and institutional research conversations.
From inquiry to study launch
A clear path for institutional partners.
Submit inquiry
Tell us your condition area, study design, and institution.
Day 0
Scoping reply
We respond with clarifying questions and a recommended study pathway.
Within 2 business days
Discovery call
20–30 minutes with the H3Pelvic team to align protocol, devices, and support.
Week 1
Research package
Technical overview, pricing, data templates, and IRB-support materials.
Week 1–2
Device shipment
Pilot units or study batch shipped after agreement and institutional processing.
Week 2–4
Study launch
Onboarding, calibration workflow, and ongoing support for data capture.
Ongoing
Apply now
Bring H3Pelvic into your research program.
Tell us about your condition area, protocol idea, institution, and timeline. We will respond with a tailored research pathway, device package, and collaboration options.
Prefer email?
Replace this placeholder with your institutional program inbox, for example research@h3pelvic.com.